← boardnext 2027-03
ALLR
Allarity Therapeuticsdistress 4/10 · elevated risk$1.280%today-35% from 52w high
Lead: ovarian cancer · est. market ~$8B (approx, global)
Revenue
pre-revenue
Liquidity
$20M
Runway
1.2 yrs
Shares 1y
+9%
Price & events
+3.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+9.4%
1W
-3.0%
1M
-8.6%
3M
+6.7%
6M
+13.3%
1Y
-74.5%
2Y
—
5Y
-100.0%
All
Overview
- Market Cap
- $20.37M
- Volume
- 6.94K
- 52 Week Range
- $0.81 – $1.97
- Total Shares
- 15.91M
- Float Shares
- 15.61M
- Short %
- 0.51%
- % Held by Insiders
- 4.19%
- % Held by Institutions
- 5.97%
- RVOL
- 0.05x
- Beta
- 0.53
Pipeline stages · 1 programs
2X-121
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-03 Estimated 50% readout ~2027-04-15 | Phase 2 | 2X-121 | Advanced Ovarian Cancer | — | recruiting |
Catalyst news & presentations · 6
- June 18, 2026conferencedata presentationsecondaryPhase 2stenoparib · Presentation of trial-in-progress poster at ESMO Gynaecological Cancers Congress 2026.SEC 8-K
- May 11–12, 2026conferencedata presentationsecondaryCEO to speak at Precision Medicine Forum Europe 2026SEC 8-K
- February 18, 2026trial initiationsecondaryPhase 2stenoparib · First patients dosed with stenoparib and temozolomide in investigator-initiated Phase 2 trialSEC 8-K
- Wednesday, October 1, 2025conferencedata presentationsecondaryPhase 2stenoparib · CEO presents on gene expression based biomarker for predicting response to stenoparibSEC 8-K
- 2025-07-15partnershipNon-exclusive global license to selected DRP algorithms in breast cancer and laboratory services agreement with EU-based biotech.SEC 8-K
- June 27, 2025trial initiationsecondaryPhase 2stenoparib · dosing of the second patient in new phase 2 trialSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-06-08Ascendiant CapitalBuy
- 2026-04-10Ascendiant CapitalBuy
- 2025-12-09Ascendiant CapitalBuy
- 2025-09-26Ascendiant CapitalBuy
- 2025-07-28Ascendiant CapitalBuy
Competitors — ovarian cancer
- ABBVAbbVie Inc.$451.1B · D2
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- CORTCORCEPT THERAPEUTICS INC$10.0B · D0
- XNCRXencor Inc$1.4B · D4
- VSTMVerastem, Inc.$515M · D5
- ZNTLZentalis Pharmaceuticals, Inc.$334M · D5
- NXTCNextCure, Inc.$16M · D9
- IMNNImunon, Inc.$7M · D8
- GMABGENMAB A/S— · D1
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-22Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year? - Yahoo Finance Australia
- 2026-07-17Allarity Therapeutics (ALLR) Edges Higher as Stock Tests Narrow Trading Range - Scalping Stock Signals - dars.gov.et
- 2026-07-14Allarity Therapeutics Q1 2026 Earnings: Narrower Loss Surpasses Expectations as Biotech Focuses on Pipeline Execution - Estimate Accuracy - dars.gov.et
- 2026-07-12DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics - TMX Newsfile
- 2026-07-07Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration - Investing News Network
- 2026-07-07Allarity Therapeutics Obtains CLIA Certification For In-House DRP Testing And Advances Stenoparib Toward FDA Registration - marketscreener.com
- 2026-07-07Allarity Therapeutics obtains CLIA lab certification - Investing.com
- 2026-07-07Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration - Yahoo Finance
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.